Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Entrada Therapeutics
Biotech
Entrada's stock craters as DMD data underperforms expectations
The phase 1/2 result underperformeds the expectations set by analysts, Novartis' rival exon 44 skipper and Entrada executives.
Nick Paul Taylor
May 7, 2026 9:12am
Altos ascends with new clinical leader—Chutes & Ladders
Aug 8, 2025 8:30am
Entrada lays off 20% of staff weeks after having FDA hold lifted
Apr 30, 2025 4:38am
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Feb 24, 2025 11:08am
Acadia brings BMS vet on board as CEO—Chutes & Ladders
Sep 27, 2024 8:30am
FDA rebuffs Entrada's attempt to get DMD clinical hold lifted
Nov 22, 2023 9:25am
